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A B S T R A C T
Multiple Sclerosis (MS) is an inﬂammatory and neurodegenerative disease, with unknown etiology. Vitamins, as
important micronutrients playing diﬀerent roles in body, seem to be important in MS pathogenesis. In vitro, in
vivo and human studies, supports the protective role of some vitamins in MS occurrence or progression. Current
study reviews recent insights and reports about the importance of vitamins in MS incidence or progression. In
accordance, the importance of all water and fat-soluble vitamins in MS pathogenesis based on observational
studies in human population and their role in the function of immune system as well as possible therapeutic
opportunities are discussed in depth throughout this review.
1. Introduction
Multiple Sclerosis (MS) is an inﬂammatory and neurodegenerative
disease, usually deﬁned by autoimmune responses to myelin sheath in
central nervous system (CNS) which causes symptoms such as optic
nerve damage, pain, fatigue, and diﬃculty in movement [1]. Despite all
available information about this disease, its etiology is still unknown.
However, it is known that MS should be studied as a neuro-in-
ﬂammatory disease as well as an autoimmune disease at the same time.
Diﬀerent risk factors such as Epstein-Barr virus infection, smoking be-
havior, season of birth, vitamin D deﬁciency, and genetic factors are
supposed to be involved in MS incidence and occurrence [2]. On the
other hand, researchers are focusing on the impact of nutrition on
disease prevalence, progression, and improvement [3–5]. Studies are
speciﬁcally investigating the eﬀect of vitamins on Alzheimer's disease
(AD) and Parkinson's disease (PD). A considerable portion of these
studies is about the vitamins and their roles. Vitamins are not every-
disease-treating elixir, but play important roles in metabolism and in
the most of vital pathways.
Vitamins such as vitamin C, vitamin A, and vitamin E act as
antioxidant agents and control oxidative stress. Studies suggest that
exogenous anti-oxidants (such as vitamin E, vitamin C, carotenoids, and
ﬂavonoids) can reduce beta-amyloid toxicity in patients with AD. A
combination of these nutrients can have preventative eﬀect on de-
mentia and cognitive impairment [6]. The association of vitamin D and
biomarkers of MS (as discussed in detail), amyotrophic lateral sclerosis
(ALS), rheumatoid arthritis, PD, and AD has studied extensively. There
are evidences to suggest positive eﬀects of high-dose vitamin D3 sup-
plementation in ALS pathophysiology [7].
There are also encouraging evidences for B family vitamins.
Restricting eﬀect of cobalamin (vitamin B12) and folate (vitamin B9) on
homocysteine (a neurotoxic metabolite) has made them considerable
nutrients. PD patients have lower serum level of cobalamin in their
serum (just like MS patients) dietary supplementation of vitamin B6
have shown to prevent PD development [8]. There is signiﬁcant asso-
ciation between serum level of thiamine (vitamin B1) and PD and its
supplementation seems to be valuable [9]. Some researchers suggest
adequate B vitamins intake should also be a public health priority [10].
However, there are few studies for conclusion and there are conﬂicting
studies, which show no clinical improvement, despite positive
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serological impacts [11]. Future studies should also investigate prob-
able side eﬀects of vitamin therapy such as mortality rate increment
[12].
In this paper, we have reviewed the relevant articles in order to
clarify the importance of each vitamin in the incidence, progression,
and improvement of MS.
2. Fat soluble vitamins
Vitamins D, A, E, and K as fat-soluble vitamins can be stored in a
long period of time and travel through the lymphatic system. They can
impose a possibility of toxicity, which is discussed separately below.
The role of fat-soluble vitamins in MS is summarized in Table 1.
2.1. Vitamin D
Vitamin D is a fat-soluble vitamin and is naturally found rarely in
foods. It is usually produced when ultraviolet (UV) ray interacts with 7-
dehydrocholesterol in the skin to form pre-vitamin D3. 25-hydro-
xycholecalciferol (25(OH)D3) is the major circulating metabolite of
vitamin D, which is measured to show the vitamin D level of patients
[13]. The primary form of vitamin D, known as cholecalciferol (vitamin
D3), is available from two sources: skin exposure to UV-B radiation in
sunlight [14].Diet can also supply cholecalciferol and ergocalciferol
(vitamin D2). In spite of sunlight exposure, diet is a poor source of
cholecalciferol, which provides only 40–400 international unit (IU) per
food serving [15] in comparison with whole-light-skinned-body ex-
posure for 20 min that produces at least 10,000 IU [16,17]. Although,
the best-known function of vitamin D is regulating calcium homeostasis
and function, it also has important eﬀects on brain development and
function, cell proliferation and apoptosis, regulation of blood pressure,
insulin secretion, diﬀerentiation of immune cells such as T-helper and
dendritic cells, and modulation of immune responses [18–20]. Ob-
servational studies, as discussed below, have demonstrated an asso-
ciation between decreased vitamin D level and risk of multiple sclerosis.
2.1.1. Vitamin D and population
Studies show that the frequency of MS incidence increases with
increasing latitude, which has strong inverse correlation with duration
and intensity of UVB of sunlight and concentrations of vitamin D
[21,22]. At high latitudes, the prevalence of MS is lower in populations,
consuming vitamin D-rich fatty ﬁsh than rest of the population, which
emphasizes the positive impact of rich diet on the status of vitamin D
[23–26]. Other vitamin D sources may also have the protective role of
fatty ﬁsh. Accordingly, the risk of MS seems to decrease with migration
from higher to lower latitudes [27]. In populations whom reside at
higher latitudes, MS is increasingly prevalent. Based on such evidences,
sunlight exposure may have protective eﬀect since at higher latitudes
lower level of sunlight leads to inadequate levels of vitamin D [28]. It
has been shown that the 25(OH)D concentration in black people is
lower comparing to white people and they often suﬀer from vitamin D
deﬁciency due to the fact that melanin pigment in human skin absorbs
UVB [29]. In contrast, studies have reported that the risk of MS in black
people is less than white people, which is probably due to genetic
factors [21,30].
Based on ecologic studies, season of birth has remarkable impact on
MS incidence which is consistent with higher risk of MS in the late ﬁrst
trimester of pregnancy due to lower sun exposure or vitamin D intake
[31]. Interestingly, analysis of all reported data showed that MS risk is
higher in those born in April and lower in those born in October and
November [32]. A study have shown that within the patient population
of 979 females and 304 males, 62% of patients were born in the spring
and summer. Additionally, the individual's risk of having MS and month
of birth was highly correlated with April, September, May, and less
correlated with November, respectively [33].
Data regarding the relevance of MS with vitamin D is controversial.
Van der Mei and colleagues have shown that patients with MS had
lower sunlight exposure during their childhood [34]. Other study have
also stated that maternal vitamin D deﬁciency during early pregnancy
imposes a nearly 2-fold increase in MS risk in the oﬀspring compared
with women with adequate 25(OH)D levels [35]. Accordingly, patients
with isolated syndrome had lower level of 25(OH)D3 comparing to
healthy controls however no signiﬁcant diﬀerence was observed in the
level of 25(OH)D2, vitamin D-binding protein, and also free or bioa-
vailable vitamin D in patients and control groups. Therefore it is sug-
gested that based on lower level of 25(OH)D3 in initial steps of MS and
in serious phases, low 25(OH)D3 level can be considered as a risk factor
for MS incidence [36]. It is also mentioned that the axonal injury can be
decreased by high 25(OH)D levels in MS [37].
2.1.2. Vitamin D and multiple sclerosis
In an investigation on the relevance of circulating plasma carriers of
vitamin D, vitamin D binding protein (DBP), and albumin in MS pa-
thogenesis, it has been shown that the plasma level of DBP is sig-
niﬁcantly higher in patients at remission phases comparing with con-
trols. However, the level of albumin was not signiﬁcantly diﬀerent
among groups [38].
Despite Smolders and colleagues study which has shown no sig-
niﬁcant correlation between DBP and relapses, there are multiple other
studies suggesting involvement of DBP in the MS pathophysiology
[39–42]. Some studies also suggest DBP isoforms in CSF as prognostic
biomarker in MS [43]. 1,25(OH)D3, as the active form of vitamin D, has
dual eﬀect on immune system by promoting the innate system response
and suppressing the adaptive immune activity. T-cells consist of dif-
ferent subgroups such as cytotoxic CD8+ T-cells, CD4+ T-helper cells
(Th cells), natural killer T cells (NKT), gamma-delta T-cells, memory,
and regulatory T-cells. The eﬀect of 1,25(OH)D3 is well characterized
on T-helper cells that their proliferation and cytokine production are
under regulation of 1,25(OH)D3 [44]. 1,25(OH)D3 has suppressing
eﬀect on producing inﬂammatory cytokines mediated by type 1 T-
helper (Th1) cells. Secretion of IL-2, IL-6, IFN gamma and macrophage
colony stimulating factor (M-CSF) are reduced by 1,25(OH)D3. Inter-
estingly, activity of immune responses mediated by Th2 cells including
the secretion of IL-3, IL-4, IL-5, IL-10, IL-13 has been enhanced by
1,25(OH)D3. It has been suggested that the positive impact of 1,25(OH)
D3 on Th2 responses might suppress the function of Th1 responses. The
Table 1
The role of fat-soluble vitamins in multiple sclerosis.




Neural- or myelin-related role Clinical remarks References
Vitamin D Low Anti-inﬂammatory Improves oxidation in white matter (at
high doses)
Risk of hypercalcaemia in the Case of
over consumption
[11–16,28,30,33–35,37–40,43,44]





Vitamin E Low No evidence Inhibits necrosis factors improves
oligodenrocytes functions
Reduces annual relapses improve
remyelination
[81–83,90–98]
Vitamin K No evidence No evidence Eﬀective in oligodendrocyte survival [99–101]
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development of regulatory T-cells is induced by 1,25(OH)D3 which
leads to the elevated level of IL-10 and TGF-beta. Additionally,
1,25(OH)D3 suppresses IL-17 secretion from Th17 cells. Collectively,
1,25(OH)D3 suppresses the responses of Th1 and Th17 and induces the
responses of regulatory T-cell (Treg). It also regulates the proliferation
and localization of Th cells. 1,25(OH)D3 can also target CD8+ T-cells
and invariant natural killer T (iNKT) cells. In vitro evidences shows that
the proliferation of CD8+ T cells are inhibited by 1,25(OH)D3 and the
proliferation of vitamin D Receptor (VDR) knockout CD8+ T-cells are
occurred independent of antigen stimulation due to over-production of
IL-2 [44–46]. Based on multiple evidences, vitamin D can have immune
regulatory role, which is crucial for suppressing inﬂammation that is
dominant in MS pathophysiology.
The maturation of human dendritic cell (DC) can be regulated by
1,25(OH)D3 and VDR. Following exposure of diﬀerentiating human
and mouse monocytes to 1,25(OH)D3, expression of molecules re-
sponsible for antigen capture is increased and DC diﬀerentiation and
maturation is inhibited that leads to the insuﬃcient stimulatory capa-
city of CD8+ T-cells speciﬁc antigen. Furthermore, the number of Treg
cells will be increased that promotes IL-10 up-regulation from CD4+ T-
cells and decreasing the level of tumor necrosis factors (TNF) and in-
terferons (IFN). Such molecules might have eﬀect on suppression and
interaction of DCs and T-cells in mice and humans. 1,25(OH)D3 can be
synthesized by immune cells including macrophages, DCs and T-cells
and can have contribution to immune responses regulation. While
1,25(OH)D3 activates VDR and 25-hydroxylase through intrinsic
pathways, the maturation of DCs will be arrested. Such inductions have
shown suspension in DCs maturation and have made them immature
phenotypically and functionally [47].
2.1.3. Vitamin D and treatment
Based on multiple evidences, boosting the serum level of vitamin D
can be an advantage for treating and preventing MS since vitamin D
supplements are cheap, convenient and safe for taking [48]. It is esti-
mated that taking enough vitamin D can help to prevent more than
110,000 deaths per year [49]. However, the so-far performed inter-
ventional trials were not able to clearly support the hypothesis that
vitamin D consumption can control the disease outcome [48]. More-
over, excess of vitamin D level in serum might lead to life-threatening
hypercalcaemia, which has been reported in some case-control studies.
It has been shown that treatment with high doses of vitamin D deri-
vatives such as cholecalciferol or ergocalciferol is more safe than cal-
citriol (1,25(OH)D3) in case of inducing symptomatic hypercalcaemia
[50,51].
2.2. Vitamin A
Vitamin A known as retinol, retinal and retinoic acid is categorized
as a fat-soluble vitamin which is involved in various number of phy-
siological functions including growth, development, immune functions
and vision. Vitamin A deﬁciency is associated with risk of infections
and can impose considerable risk of mortality and morbidity world-
wide. Roles of vitamin A in immune system functions are documented
in a large scale. On the other hand, its roles in brain development and
activity is elicited [52].
2.2.1. Vitamin A and population
It has been shown that the low level of vitamin A might be asso-
ciated with the risk of MS [53]. Also, level of neutrophilic glutathione
peroxidase (GSH-Px), vitamin A, and vitamin E are reported to be lower
in serum of MS patients [54].
A study contributing 88 relapse-remitting MS patients reported a
negatively associated level of serum retinol and magnetic resonance
imaging (MRI) output [55]. Additionally, the retinol plasma level of MS
patients under IFN-beta1a therapy is reported to be higher comparing
to untreated groups, and also an expression of retinoid receptor
subtypes is observed in mentioned patients which further emphasized
on the association of retinol plasma level and activity of speciﬁc re-
tinoid receptor subtypes [56]. Vitamin A inhibits diﬀerentiation of
Th17 and promotes Treg diﬀerentiation so it may be involved in disease
course of MS. Some studies have reported no correlation between vi-
tamin A serum level and relapse rate. However, they have reported a
positive correlation between vitamin A and vitamin D serum level,
which might be due to the patients' diet. Accordingly, it has been
suggested that retinoic acid has tissue speciﬁc manner and its local
production in CNS might cause relapse courses [57,58]. Based on these
population studies, vitamin A can be considered as a signiﬁcant mi-
cronutrient in pathophysiology of the disease more extended studies are
needed for a strong conclusion.
2.2.2. Vitamin A and multiple sclerosis
Astrocyte derived retinoic acid (RA) plays considerable role in de-
velopment and formation of blood-brain barrier (BBB) [59]. It has been
shown that the expression of retinaldehyde dehydrogenase 2 (RALDH2)
as a critical enzyme for the synthesis of RA is enhanced in reactive
astrocytes in MS lesions. Additionally, over-expression of RALDH2 and
higher levels of RA improve the restoration of the BBB integrity after its
disruption due to such inﬂammatory factors as TNF in MS patients. It
has been suggested that antioxidant transcription factor nuclear E2-
related factor (Nrf2) is involved in protective role of RA and attenuates
reactive oxygen species (ROS) levels in BBB lesions [60]. Accordingly,
RA reduces the expression of IL-6, chemokine CeC motif ligand 2
(CCL2), and vascular cell adhesion molecule (VCAM-1) in brain en-
dothelium which is increased under the inﬂammation state. Therefore,
RA might serve as a potential therapeutic agent to reduce neuro-in-
ﬂammatory diseases consequences. Moreover, Retinoid x receptor
gamma (RXR-γ) has positive eﬀect on oligodendrocyte diﬀerentiation
and stimulates remyelination of injured CNS, positively [61]. Further-
more, there is evidence that RA receptors and vitamin D in hetero-
dimerisation with RXR are able to bind hormone response elements and
stimulate or repress transcription of certain target genes. However the
pattern of their combination determines their eﬀect on gene expressions
[62]. Studies have shown that the circulatory level of RA and expres-
sion of RA-related genes can be inﬂuenced by external light in animal
models [63,64].
Retinoid-related orphan receptor gamma (RORγ) is responsible for
survival of immune cells such as Th17 in experimental autoimmune
encephalomyelitis (EAE) model and is stimulated by melatonin fol-
lowing light exposure. RORγ is negatively activated by all-trans-retinoic
acid. Therefore, the number of Th17 and IL17 level can be regulated by
light dependent vitamin A [65]. As a result of supplementation with
vitamin A, down-regulation of RAR-alpha [66] and IL-17 and ROR-
gamma in peripheral mononuclear cells derived from the patients'
blood [67] has been reported.
Retinoid molecules including all-trans-retinoic acid have been
shown to suppress demyelination of CNS in EAE models which is as-
sociated with decreased IFN-gamma and TNF-alpha mRNA expression
level and increased IL-4 and decreased IL-2 production by immune cells
[68–70]. Deﬁciency of vitamin A is associated with decreased produc-
tion of IL-4 and IL-10 and enhanced production of IFN-gamma [71–75].
The eﬀect of vitamin A on IL-10 secretion from Th2 cells has been
mentioned by many studies. It has been shown that the synthesis of IL-2
as an inﬂammatory cytokine by Th1 cells is inhibited by IL-10. Ad-
ditionally, the level of IL-10 secretion from B-cells derived from MS
patients were enhanced by RA administration and treating B-cells of MS
patients by glatiramer acetate or IFN-beta-1b is able to retain this eﬀect.
Accordingly, RA aﬀects positively IgG secretion and proliferation of B-
cells in MS patients under stimulation by TLR9/RP105 [76].
2.2.3. Vitamin A and treatment
IFN-beta-1a and b are the most used treatments against MS, which
reduces the frequency of MS attacks and disease burden. In order to
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determine the possible role of RA as a booster for IFN-beta, it has been
shown that RA alone is able to reduce the count of IFN-gamma secreting
cells but it has no eﬀect on proliferation of T-cells. Additionally, RA in
combination with IFN-beta-1b can potentiate the restoration of defec-
tive T-suppressor cell function [77]. Studies have shown that supple-
mentation with retinyl palmitate, a retinol ester that can be converted
to retinol [78], reduces myelin oligodendrocyte protein (MOG)-induced
proliferation of T-cells derived from MS patients in vitro. This eﬀect can
be a result of reduction in production of IL-2 [79,80]. IL-10 has been
also shown to be involved in suppressing T-cell mediated autoimmunity
in EAE [81].
In another study, the eﬀect of vitamin A on disease progression of
101 patients with MS is evaluated. The results shows that vitamin A,
administered as retinyl palmitate, suppresses the progression of upper
limbs and cognitive disabilities but not those of the lower limbs in MS
patients. These results were achieved by comparing multiple sclerosis
functional composite (MSFC) and expanded disability status scale
(EDSS) scores. MSFC score, an index for physical functioning, was im-
proved in treated group but no signiﬁcant diﬀerence in EDSS score, and
index of disabilities, was observed. There were also no signiﬁcant
changes in white matter lesions and relapse rates. The authors sug-
gested that vitamin A may have better eﬀect on neurodegenerative
features rather than inﬂammatory features of MS [82]. A synthetic re-
tinoid, Etretinate, has also been shown to potentiate the eﬀect of IFN-
beta-1b on cell function suppression [83]. It is suggested that vitamin A
supplementation can be beneﬁcial to relief inﬂammation and useful for
protecting the brain. Although, we may see this beneﬁt in patients in
degenerative phase and further, vitamin A supplementation is re-
commended to be a part of MS therapeutic program [84]. Despite these
ﬁndings, an extensive cohort study on the relevance of receiving car-
otenoids, vitamins C and E, and the risk of MS have shown no notice-
able reduction in the risk due to vitamin-rich diet [85]. It is north
worthy that ingestion of diﬀerent preparations of vitamin A and dif-
ferent length of consumption can lead to signiﬁcant variable plasma
level of vitamin A in healthy subjects and may interfere the conclusions
[86,87]. Based on these ﬁndings, vitamin A seems to be valuable in
suppressing neurodegenerative or inﬂammatory conditions of MS pa-
tients but more studies under controlled situations with stronger
methodology are needed for a trustable conclusion.
2.3. Vitamin E
Vitamin E belongs to the family of tocopherols and tocotrienols and
has distinctive antioxidant activities in body. Additionally, it has been
shown that vitamin E is involved in regulation of gene expression, ac-
tivity of immune system and modulating cell signaling.
2.3.1. Vitamin E and population
Comparing CSF and serum levels of vitamin E in 36 Patients of MS
and 32 matched control, has shown that the serum vitamin E and vi-
tamin E/cholesterol ratio were signiﬁcantly lower in patients. However,
the mean CSF vitamin E levels and the CSF/serum vitamin E ratio did
not vary signiﬁcantly between the two study groups [88]. These ﬁnd-
ings were supported by two other studies reporting a decrease level of
vitamin E in the body in patients with multiple sclerosis [89,90]. Fur-
thermore, it is observed that the ratio of plasma vitamin E to cholesterol
and triglyceride are decreased during MS exacerbation and increased
during treatment with IFN-beta [91]. It is shown that this increment is
not a direct result of IFN-beta treatment [92] so it might be due to
disease suppression and suggests an overproduction of free radicals
during the active phase of the disease. Consequently, consumption of
antioxidant molecules such as alpha-tocopherol can relief the adverse
eﬀects. There are evidence that the levels of alpha-tocopherol and
glutathione are decreased in demyelinating plaques of patients with
multiple sclerosis [93].
Seemingly, natural doses of vitamin E does not have signiﬁcant
protective roles and studies have failed to show MS risk improvement
by dietary intakes of vitamins E and C [94,95]. A prospective study
among two large cohorts of women did not ﬁnd any association be-
tween higher intakes of vitamin E and reduced risk of MS [85,96].
Increasing serum concentrations of alpha-tocopherol has been as-
sociated with reduced odds for simultaneous and subsequent MRI dis-
ease activity in relapsing-remitting MS patients during IFN-beta treat-
ment [97]. In a clinical study, a mixture of several polyunsaturated
fatty acids (PUFAs), mono unsaturated fatty acids (MUFAs), saturated
fatty acids along with vitamins E and A, signiﬁcantly reduced annual
relapse rate, and the risk of sustained disability progression compared
to control. Vitamin E was reported to be a necessary component of this
mixture but it did not decrease annual relapse rate meaningfully while
administered alone [98].
2.3.2. Vitamin E and multiple sclerosis
In animal models, the eﬀect of vitamin E on the state of myelin has
been investigated. Vitamin E in conjunction with Ebselen, both having
antioxidant properties, protects against ethidium bromide induced de-
myelination and interferes with the cholinergic neurotransmission by
altering acetylcholine esterase activity in various brain regions and in
the erythrocytes [99]. Also, it is reported that vitamin E increases en-
dogenous remyelination of hippocampus in addition to reducing the
damage caused by ethidium bromide in rats [100].
Studies on therapeutic eﬀects of tocopherol derivative, TFA-12, in
EAE mice models revealed that TFA-12 promotes oligodendrocyte re-
generation and remyelination and reduces inﬂammation, astrogliosis,
and myelin loss. In addition, TFA-12 induces the oligodendrocyte pre-
cursor cells diﬀerentiation into mature oligodendrocytes by inhibiting
of the Notch/Jagged1 signaling pathway [101].
Several studies have stated that vitamin E can inhibit NF-kB, a
transcription factor involved in cell apoptosis and proliferation, in
diﬀerent cell types [102–104]. NF-kB is reported to be induced in the
spinal cord of EAE rat models and its activation is persistent throughout
the disease period and decreases during the recovery phase. In vivo
inhibition of NF-kB activation by pyrrolidine diticarbomate results in
attenuation of EAE clinical symptoms [105]. In light of these ﬁndings, it
is conceivable that vitamin E by inhibiting NF-kB could have ther-
apeutic importance in MS.
2.4. Vitamin K
No observational study was found regarding vitamin K deﬁciency
and MS pathogenesis, which might be due to the fact that vitamin K
deﬁciency is uncommon. However two studies have mentioned the
importance of growth arrest speciﬁc gene 6 (Gas6) which is a vitamin K-
dependent gene having role in MS progression [106,107]. This vitamin
K-dependent gene is believed to play role in survival of oligoden-
drocytes and as the result improvement of myelination in the CNS. Gas6
is also an important factor in sphingolipid synthesis which seems to be
important in remyelination [108]. However, no study was found to
report observations based on EAE or any intervention and clinical trial
on individuals and further investigations are required to clarify the
possible correlation of vitamin K in pathophysiology of MS.
3. Water soluble vitamins
Vitamins C, B1, B3, B6, B9, and B12 are water-soluble vitamins, which
are believed to play considerable role in incidence, progression, or
treatment of multiple sclerosis. The role of water-soluble vitamins in MS
is summarized in Table 2.
3.1. Vitamin C
Ascorbate plays a role in synthesis of collagen which itself is asso-
ciated with myelin formation. Study has shown that intra-hippocampal
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injection of vitamin C improves memory for passive avoidance learning
in Wistar rats [109]. This ﬁnding is important as more than 65% of
patients with MS show signs of cognitive impairment and usually their
ability to recall previously learned information reduces [110]. Epide-
miological studies have found no reduction in MS risk with the intake of
antioxidant vitamins such as vitamin C [111]. A study on the potential
importance of uric acid has revealed that it has a remarkable eﬀect on
preventing the development of EAE symptoms or reducing them in
comparison with ascorbic acid [112]. Additionally, high levels of vi-
tamin C can be potentially harmful for patients due to promoting
Fenton's reaction, a reaction that produces hydroxyl radicals in iron-
rich tissues such as brain or spinal cord white matter. As the reduced
form of iron ion, ferrous, is a part of this reaction, high concentrations
of anti-oxidants such as vitamin C can promote it and as the result, may
worsen inﬂammatory state due to radical production [113–115]. As a
result, using vitamin C in therapeutic doses may worsen inﬂammatory
diseases such as MS by promoting the Fenton's reaction [116]. It is
reported that administration of vitamin C, not only shows no protective
role against EAE development, but also worsens lipid peroxidation both
in vivo and in vitro in the presence of Fe3+[112].
3.2. Vitamin B9 and B12
Folate (vitamin B9) and cobalamin (vitamin B12) are known as two
key micronutrients in individuals. These two vitamins are considered as
important cofactors in methylation reactions that makes them crucial
for DNA synthesis and repair, metabolism of fatty acids and some amino
acids, and also normal functioning of nervous system [117]. These two
vitamins are also important cofactors for metabolism of homocysteine
to methionine. Deﬁciency of cobalamin and folate is one of the most
commonly seen deﬁciencies in patient suﬀering from MS and in most of
the cases, high levels of homocysteine is observed. Homocysteine is a
neurotoxic substance that cellular studies [118–120] as well as epide-
miological studies [121,122] suggest that it can be harmful for the CNS
as an inﬂammatory and a neurodegenerative agent. Folate and coba-
lamin are known as important cofactors for homocysteine uptake [123].
Evidences show that serum levels of cobalamin and folate is de-
creased in relapsing-remitting patients in comparison with control
group. Increased level of homocysteine is also observed in mentioned
patients [124]. Another study has also shown that some patients with
multiple sclerosis are also suﬀering from megaloblastic anemia or
macrocytosis as a sign of B12 deﬁciency [125]. There are also other
studies, which have reported mild macrocytosis or borderline low
serum B12 concentration in MS patients [126,127] and others have
reported high levels of homocysteine in serum of MS patients
[128,129]. A meta-analysis [130] also supports this observations and
claims that B12 and folate are in low levels in MS patients and homo-
cysteine level is higher than healthy people.
B12 also is an important cofactor in formation of myelin sheath
[131]. It also incorporates in the modulation of immune system by
having role in modulation of cytokines TNF-gamma activity so that
cobalamin deﬁciency may worsen the inﬂammations that might be seen
in MS [132].
In contrast, some studies have reported no correlation between fo-
late or cobalamin and MS [90] but some have mentioned that in spite of
normal B12 serum level in these cases, the unsaturated B12 binding
capacity was higher that can be considered as a sign for body demand
[133]. Multiple treatments with cobalamin and folate have also been
reported with improvements in EDSS scores or decrease relapse risk
[133,134].
3.3. Vitamin B6
Vitamin B6 and its active form, pyridoxal 5′-phosphate (PLP) play
key roles in metabolism of amino acids, sugars, and lipids. As its sig-
niﬁcant functions, involvement in neurotransmitter synthesis, gene
expression, or transamination can be mentioned [135].
Few studies were found on the correlation of B6 vitamin and MS.
There is controversy in studies as normal or higher than normal serum
levels of vitamin B6 is reported, and in contrast other studies have re-
ported decreased serum levels of B6 in comparison with control group
have reported that B6 serum level was normal in MS patients or higher
than control group in some cases [90,136]. However, B6 seems to play
important roles in synthesizing sphingomyelins such as myelin sheath
[137]. B6 is one of the cofactors in homocysteine uptake which has
neurotoxic and neuroinﬂammatory roles as discussed above [136].
However, as B6 is not the main cofactor comparing with B9 and B12, and
a study have reported no signiﬁcant correlation between B6 and
homocysteine serum level [138], homocysteine uptake from B6-de-
pendent pathway leads to cysteine which is an amino-acid having role
in myelin formation. It is suggested that nitric-oxide produces perox-
initrate which is a highly active radical and consuming B6 vitamin daily
during adolescence may reduce the risk of myelin damage [139].
3.4. Vitamin B3
Vitamin B3 also known as nicotinic acid or niacin is another water-
soluble micronutrient, which plays essential roles as nicotinamide
adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide
phosphate (NADP) as two important coenzymes in hydrogen transfer-
ring processes. Investigations have shown the role of niacin deﬁciency
in cardiovascular diseases [140] as well as its active forms, NAD and
NADP, roles in neural mechanisms such as lipid metabolism or DNA
repair [141].
Few studies are devoted to determine the relevance of nicotinic acid
and MS. Oﬀermanns and Schwaninger have mentioned that ketone
bodies, dimethyl fumarate (DMF), and nicotinic acid involving hydro-
xycarboxylic acid 2 receptors can reduce inﬂammation in neural system
[142]. It has reported that rats with nicotinic-acid deﬁciency had less
long-chain fatty acid than those favoring B3-rich diet [143]. Treating
patients with cytoﬂavin, a combination of nicotinamide and riboﬂavin
(vitamin B2), is reported to cause improvement in EDSS score, which
might be another evidence for vitamin B3 value for clinical purposes
[144].
Table 2
The role of water-soluble vitamins in multiple sclerosis.




Neural- or myelin-related role Clinical remarks References
Vitamin C High No evidence Eﬀective in dendritic cell maturation Not suggested [102,105–109]





Vitamin B6 Controversial No evidence Eﬀective in myelin synthesization Reduces the risk of myelin
damage
[129,130]
Vitamin B3 Controversial No evidence Reduces inﬂammation Improves EDSS [135–137]
Vitamin B1 Controversial No evidence Increases T-cell proliferation Reduces fatigue [138–140]
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3.5. Vitamin B1
Vitamin B1 is not considered as much as other vitamins regarding
MS pathogenesis but there are studies suggesting that thiamine has
important roles in nervous system [145,146]. Thiamine deﬁciency
causes increased CeC chemokine ligand 2 (CCL2) expression in spinal
cord and T-cell proliferation in EAE mice model, which worsens the
symptoms [147]. Human study also reports that MS patients intervened
by thiamine, experienced improvement in their fatigue which might be
due to the B1 role in oxidative phosphorylation in mitochondria [148].
However, there are few studies in this ﬁeld to make a strong conclusion
whether thiamine is valuable for MS patients or not.
4. Conclusion
In this review, we tried to clarify the role of vitamins in MS.
Vitamins are important micronutrients that play diﬀerent roles in our
body. As discussed above, evidences strongly suggest that vitamins D,
B12, and B9 can have considerable roles in MS pathogenesis. On the
other side, supplementation of vitamins A, E, and B1 can also be ben-
eﬁcial in order to decelerate MS progression or improve unfavorable
conditions such as fatigue and cognitive impairments. Vitamin C sup-
plimentation, despite its antioxidant roles, may worsen patients con-
ditions by stimulation Fenton's reaction in the CNS white matter, as
mentioned.
The relevance of vitamins in MS pathophysiology have been ex-
plored extensively. However, the exact role of each vitamin is required
to be investigated in MS. Evidences on the eﬀect of some vitamins and
their possible roles are lacking. More trials in order to establish new
treatment approaches based on vitamins are recommended due to un-
known etiology of MS which might open up new opportunities to de-
velop more eﬃcient therapeutic strategies.
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